277
Participants
Start Date
October 31, 2010
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Ranibizumab
0.5 mg ranibizumab intravitreal injection
Verteporfin PDT
Verteporfin (6 mg/m2) intravenous infusion
Sham Ranibizumab
Empty vial to mimic the intravitreal injection
Sham verteporfin PDT
Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
Novartis Investigative Site, Riga
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Budapest
Novartis Investigative Site, Vienna
Novartis Investigative Site, Geneva
Novartis Investigative Site, Bern
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Linz
Novartis Investigative Site, Berlin
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Dijon
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Udine
Novartis Investigative Site, Valladolid
Novartis Investigative Site, Bilbao
Novartis Investigative Site, Münster
Novartis Investigative Site, Münster
Novartis Investigative Site, Florence
Novartis Investigative Site, Cologne
Novartis Investigative Site, Reims
Novartis Investigative Site, Bonn
Novartis Investigative Site, Bari
Novartis Investigative Site, Paris
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, München
Novartis Investigative Site, Bratislava
Novartis Investigative Site, Nuremberg
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Singapore
Novartis Investigative Site, Singapore
Novartis Investigative Site, Mumbai
Novartis Investigative Site, Bangalore
Novartis Investigative Site, Chennai
Novartis Investigative Site, Madurai
Novartis Investigative Site, Singapore
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Montreal
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kita-gun
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Matsumoto
Novartis Investigative Site, Hirakata
Novartis Investigative Site, Suita
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Mitaka
Novartis Investigative Site, Kaunas
Novartis Investigative Site, Vilnius
Novartis Investigative Site, Bielsko-Biala
Novartis Investigative Site, Coimbra
Novartis Investigative Site, Porto
Novartis Investigative Site, Banská Bystrica
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Alicante
Novartis Investigative Site, Ankara
Novartis Investigative Site, Ankara
Novartis Investigative Site, Etlik / Ankara
Novartis Investigative Site, Belfast
Novartis Investigative Site, Bristol
Novartis Investigative Site, Wolverhampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY